Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Nivolumab and allogeneic transplantation in R/R classical Hodgkin lymphoma

Charles Herbaux • 10 Jun 2020
EHA 2020
Hodgkin Lymphoma Lymphoma Antibodies Checkpoint inhibitors Nivolumab

Charles Herbaux MD, MSc, CHU de Lille, Lille University Hospital, Lille, France, outlines issues with checkpoint inhibition after allogeneic transplantation in regards to refractory/relapsed (R/R) classical Hodgkin lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Charles Herbaux

1:46
Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL
Charles Herbaux • 25 May 2021
1:26
Ruxolitinib plus venetoclax for T-PLL: rationale and findings
Charles Herbaux • 25 May 2021
4:23
LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCL
Charles Herbaux • 10 Jun 2020

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals